Wednesday, 22 January 2025
  
Login

Australia's most trusted
source of pharma news

Wednesday, 22 January 2025
News

Pharmas earning big PBS bucks

Posted 16 January 2025 AM

Johnson & Johnson Innovative Medicine (Janssen) and Novartis remained the biggest PBS players during the financial year ending 2024, each earning $1 billion for a third consecutive year, according to the latest PBS Expenditure and Prescriptions Report.

The values given in the report are for Section 85 and Section 100 drugs, excluding Efficient Funding of Chemotherapy items, and including Doctors' Bag and under co-payment prescriptions. This means the current highest earner on the PBS, MSD's blockbuster cancer drug Keytruda is excluded from the list. 

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (5)

Sales & Customer Relations (14)

Clinical & Medical, R&D (5)

Regulatory, Pharmacovigilance & QA (2)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.